NASDAQ:PTCT - PTC Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $62.22
Forecasted Upside: 50.95 %
Number of Analysts: 11
Breakdown:
0 Sell Ratings
4 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$41.22 As of 07/23/2021 01:00 AM ET

▼ -0.86 (-2.04%)

1 month | 3 months | 12 months

Get New PTC Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PTCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTCT

^$62.22

▲ +50.95% Upside Potential

This price target is based on 11 analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $62.22, with a high forecast of $75.00 and a low forecast of $47.00. The average price target represents a 50.95% upside from the last price of $41.22.

Current Consensus is Buy

The current consensus among 11 polled investment analysts is to buy stock in PTC Therapeutics. This rating has held steady since May 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
5 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

1/31/2020

0 strong buy ratings
4 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

4/30/2020

0 strong buy ratings
4 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/29/2020

0 strong buy ratings
6 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/27/2020

0 strong buy ratings
7 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

1/25/2021

0 strong buy ratings
6 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

4/25/2021

0 strong buy ratings
8 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

6/24/2021

0 strong buy ratings
7 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/3/2021	William Blair	Reiterated Rating	Buy		High
5/17/2021	Truist Securities	Lower Price Target	Buy	$75.00 ➝ $65.00	Low
5/17/2021	Truist	Lower Price Target	Buy	$75.00 ➝ $65.00	Low
4/26/2021	Credit Suisse Group	Initiated Coverage	Neutral	$54.00	High
3/29/2021	Royal Bank of Canada	Upgrade	Underperform ➝ Sector Perform	$47.00	Medium
2/26/2021	Cantor Fitzgerald	Lower Price Target	Overweight	$81.00 ➝ $75.00	High
2/12/2021	Bank of America	Downgrade	Buy ➝ Neutral		Low
1/5/2021	Smith Barney Citigroup	Upgrade	Neutral ➝ Buy		N/A
12/16/2020	Raymond James	Boost Price Target	Outperform	$63.00 ➝ $70.00	Medium
11/30/2020	Royal Bank of Canada	Downgrade	Sector Perform ➝ Underperform	$45.00	High
10/30/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		Medium
10/30/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$75.00 ➝ $67.00	High
10/28/2020	UBS Group	Initiated Coverage	Neutral	$55.00	Medium
10/7/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$71.00	High
9/23/2020	Raymond James	Reiterated Rating	Buy		Medium
8/24/2020	Raymond James	Initiated Coverage	Outperform	$63.00	High
8/11/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$85.00 ➝ $75.00	Low
8/10/2020	Bank of America	Lower Price Target	Buy	$60.00 ➝ $58.00	Medium
8/10/2020	Credit Suisse Group	Lower Price Target	Neutral	$53.00 ➝ $52.00	Low
7/20/2020	Cowen	Reiterated Rating	Hold	$50.00	High
7/20/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$53.00	High
7/20/2020	SunTrust Banks	Boost Price Target	Buy	$75.00 ➝ $86.00	High
5/1/2020	SunTrust Banks	Lower Price Target	Buy	$78.00 ➝ $75.00	Medium
4/28/2020	William Blair	Reiterated Rating	Buy		Low
4/9/2020	Citigroup	Upgrade	Neutral ➝ Buy	$71.00 ➝ $67.00	High
4/8/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$86.00 ➝ $85.00	Medium
4/8/2020	Royal Bank of Canada	Reiterated Rating	Hold	$45.00	High
3/4/2020	Barclays	Reiterated Rating	Hold	$51.00	High
3/3/2020	Cantor Fitzgerald	Reiterated Rating	Positive ➝ Overweight	$81.00 ➝ $86.00	High
3/2/2020	Cowen	Reiterated Rating	Hold		High
2/20/2020	Citigroup	Downgrade	Buy ➝ Neutral	$55.00 ➝ $71.00	High
2/20/2020	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$63.00 ➝ $60.00	High
2/6/2020	SunTrust Banks	Reiterated Rating	Buy	$78.00	Medium
2/6/2020	Cowen	Reiterated Rating	Hold		High
1/23/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$60.00 ➝ $81.00	Low
1/15/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$60.00	Medium
12/5/2019	Royal Bank of Canada	Reiterated Rating	Outperform	$58.00	Medium
11/26/2019	William Blair	Reiterated Rating	Buy		Low
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$78.00	Low
10/31/2019	Credit Suisse Group	Reiterated Rating	Buy	$54.00	Low
10/30/2019	Cowen	Reiterated Rating	Hold		High
9/26/2019	Citigroup	Set Price Target	Buy	$62.00	High
9/24/2019	Royal Bank of Canada	Reiterated Rating	Buy		High
8/12/2019	Barclays	Reiterated Rating	Hold	$43.00	Low
5/13/2019	Bank of America	Upgrade	Neutral ➝ Buy	$43.00 ➝ $49.00	Low
5/8/2019	Cowen	Reiterated Rating	Hold		High
5/3/2019	Citigroup	Set Price Target	Buy	$59.00	Low
5/2/2019	Cowen	Reiterated Rating	Hold		High
4/11/2019	Sanford C. Bernstein	Initiated Coverage	Outperform	$48.00	Low
2/28/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$61.00	High
1/29/2019	Credit Suisse Group	Set Price Target	Buy	$51.00	High
1/7/2019	William Blair	Reiterated Rating	Buy		High
1/7/2019	Credit Suisse Group	Reiterated Rating	Buy	$55.00	High
1/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$61.00	High
11/12/2018	Cantor Fitzgerald	Lower Price Target	Overweight ➝ Overweight	$66.00 ➝ $61.00	High
11/6/2018	Royal Bank of Canada	Lower Price Target	Outperform ➝ Outperform	$51.00 ➝ $46.00	High
11/6/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$43.00 ➝ $40.00	High
11/6/2018	William Blair	Reiterated Rating	Buy		High
11/5/2018	Credit Suisse Group	Set Price Target	Buy	$55.00	High
10/3/2018	Bank of America	Upgrade	Underperform ➝ Neutral		High
10/3/2018	Credit Suisse Group	Set Price Target	Buy	$55.00	Medium
10/3/2018	William Blair	Reiterated Rating	Buy		High
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$66.00	Medium
9/28/2018	JPMorgan Chase & Co.	Boost Price Target	Positive ➝ Neutral	$51.00	Low
9/5/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$49.00 ➝ $53.00	Low
8/8/2018	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $43.00	High
7/31/2018	Bank of America	Boost Price Target	Underperform ➝ Underperform	$27.00 ➝ $31.00	High
7/24/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $50.00	Low
7/19/2018	Credit Suisse Group	Initiated Coverage	Outperform	$49.00	High
6/20/2018	Barclays	Upgrade	Underweight ➝ Equal Weight		High
6/18/2018	William Blair	Upgrade	Market Perform ➝ Outperform		High
6/18/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$11.00	High
5/10/2018	William Blair	Reiterated Rating	Hold		High
4/3/2018	Barclays	Downgrade	Equal Weight ➝ Underweight	$24.00 ➝ $26.00	High
3/7/2018	Barclays	Reiterated Rating	Equal Weight ➝ Equal Weight	$18.00 ➝ $24.00	High
3/7/2018	William Blair	Reiterated Rating	Hold		High
2/21/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $35.00	High
1/30/2018	Credit Suisse Group	Reiterated Rating	Buy	$28.00	Medium
1/29/2018	Royal Bank of Canada	Initiated Coverage	Sector Perform ➝ Sector Perform		High
1/23/2018	Barclays	Reiterated Rating	Hold		Low
11/24/2017	JPMorgan Chase & Co.	Boost Price Target	Underweight ➝ Neutral	$15.00	N/A
11/16/2017	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$15.00	N/A
10/26/2017	Bank of America	Downgrade	Neutral ➝ Underperform		N/A
10/25/2017	Cowen	Reiterated Rating	Hold		N/A
10/25/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00	N/A
10/9/2017	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$23.00 ➝ $15.00	N/A
9/29/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform		High
9/29/2017	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$22.00 ➝ $15.00	High
9/27/2017	Citigroup	Reiterated Rating	Buy	$28.00	Low
9/26/2017	Credit Suisse Group	Reiterated Rating	Outperform	$25.00	High
9/26/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		High
9/8/2017	Barclays	Reiterated Rating	Hold	$22.00	Low
8/23/2017	William Blair	Initiated Coverage	Mkt Perform ➝ Market Perform	$17.00	Low
7/20/2017	Citigroup	Reiterated Rating	Buy	$28.00 ➝ $17.00	High
6/30/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	$15.00 ➝ $21.00	Low
6/7/2017	Citigroup	Set Price Target	Buy	$15.00 ➝ $18.00	High
5/8/2017	Royal Bank of Canada	Set Price Target	Hold	$12.00	High
3/22/2017	Barclays	Reiterated Rating	Equal Weight	$13.00	Medium
3/16/2017	Cowen	Reiterated Rating	Hold		High
3/16/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$13.00 ➝ $10.00	High
3/6/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$13.00	N/A
3/6/2017	Credit Suisse Group	Reiterated Rating	Outperform ➝ Positive	$25.00	N/A
3/3/2017	Barclays	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $13.00	N/A
2/16/2017	Credit Suisse Group	Reiterated Rating	Positive		N/A
1/10/2017	Jefferies Financial Group	Reiterated Rating	Hold	$12.00	N/A
1/2/2017	Royal Bank of Canada	Set Price Target	Hold	$13.00	N/A
11/14/2016	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$15.00 ➝ $25.00	N/A
11/11/2016	Wedbush	Reiterated Rating	Neutral	$12.00 ➝ $7.00	N/A
11/11/2016	Royal Bank of Canada	Boost Price Target	Hold	$13.00	N/A
11/11/2016	Royal Bank of Canada	Lower Price Target	Sector Perform	$13.00	N/A
11/11/2016	Citigroup	Upgrade	Neutral ➝ Buy	$7.00 ➝ $15.00	N/A
11/4/2016	Cowen	Reiterated Rating	Market Perform		N/A
11/3/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$15.00	N/A
11/3/2016	Wedbush	Reiterated Rating	Neutral	$7.00 ➝ $10.00	N/A
10/11/2016	Wedbush	Reiterated Rating	Neutral	$10.00	N/A
10/11/2016	Credit Suisse Group	Boost Price Target	Neutral	$15.00	N/A
10/3/2016	Bank of America	Reiterated Rating	Hold	$15.00	N/A
9/22/2016	Jefferies Financial Group	Reiterated Rating	Hold	$7.00	N/A
8/8/2016	Citigroup	Boost Price Target	Neutral	$8.00 ➝ $9.00	N/A
8/7/2016	Cowen	Reiterated Rating	Hold		N/A
8/5/2016	JPMorgan Chase & Co.	Lower Price Target	Neutral	$18.00 ➝ $17.00	N/A
8/5/2016	Credit Suisse Group	Set Price Target	Hold	$6.00	N/A
8/5/2016	Wedbush	Reiterated Rating	Neutral	$10.00	N/A
8/2/2016	Citigroup	Reiterated Rating	Buy	$48.00	N/A
7/26/2016	Wedbush	Lower Price Target	Neutral	$12.00 ➝ $10.00	N/A
7/26/2016	Credit Suisse Group	Downgrade	Outperform ➝ Neutral		N/A

(Data available from 7/25/2016 forward)

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $41.22

$41.08

$42.50

50 Day Range

MA: $41.93

$37.95

$44.74

52 Week Range

Now: $41.22

$37.12

$70.82

Volume

236,512 shs

Average Volume

364,176 shs

Market Capitalization

$2.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?

The following sell-side analysts have issued research reports on PTC Therapeutics in the last twelve months: Bank of America Co., Cantor Fitzgerald, Credit Suisse Group AG, JPMorgan Chase & Co., Raymond James, Royal Bank of Canada, Smith Barney Citigroup, Truist, Truist Securities, UBS Group AG, William Blair, and Zacks Investment Research.
View the latest analyst ratings for PTCT.

What is the current price target for PTC Therapeutics?

9 Wall Street analysts have set twelve-month price targets for PTC Therapeutics in the last year. Their average twelve-month price target is $62.22, suggesting a possible upside of 51.0%. Cantor Fitzgerald has the highest price target set, predicting PTCT will reach $75.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $47.00 for PTC Therapeutics in the next year.
View the latest price targets for PTCT.

What is the current consensus analyst rating for PTC Therapeutics?

PTC Therapeutics currently has 4 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTCT will outperform the market and that investors should add to their positions of PTC Therapeutics.
View the latest ratings for PTCT.

What other companies compete with PTC Therapeutics?

Other companies that are similar to PTC Therapeutics include Ono Pharmaceutical, Maravai LifeSciences, Grifols, Bausch Health Companies, CureVac, Jazz Pharmaceuticals, Teva Pharmaceutical Industries, BridgeBio Pharma, United Therapeutics, Biohaven Pharmaceutical, Mirati Therapeutics, Arrowhead Pharmaceuticals, Evotec, HUTCHMED and Legend Biotech.

How do I contact PTC Therapeutics' investor relations team?

PTC Therapeutics' physical mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company's listed phone number is 908-222-7000 and its investor relations email address is [email protected] The official website for PTC Therapeutics is www.ptcbio.com.